Melatonin after eye melanoma to lower spread risk
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign consent
- Your melanoma must start in the eye’s choroid or ciliary body
- Your tumor must be higher-risk based on tumor size, stage, or lab test features
- There must be no current evidence of spread to other organs
- You must not be pregnant or breastfeeding, and you must use pregnancy prevention if able to become pregnant
- You should not be unable to safely take melatonin (no allergy, no epilepsy, healthy enough liver)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This early-phase study tests whether melphalan can be used to reduce (shrink) a type of eye cancer called choroidal melanoma before additional treatment. It may help by controlling tumor size while doctors closely monitor the eye and outcomes.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.